Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study.
Tais Basaco Bernabeu, Rosalba Mansi, Luigi Del Pozzo, Raghuvir Haridas Gaonkar, Lisa McDougall, Anass Johayem, Milen Blagoev, Francesco De Rose, Leila Jaafar-Thiel, Melpomeni Fani
{"title":"Copper-61 is an advantageous alternative to gallium-68 for PET imaging of somatostatin receptor-expressing tumors: a head-to-head comparative preclinical study.","authors":"Tais Basaco Bernabeu, Rosalba Mansi, Luigi Del Pozzo, Raghuvir Haridas Gaonkar, Lisa McDougall, Anass Johayem, Milen Blagoev, Francesco De Rose, Leila Jaafar-Thiel, Melpomeni Fani","doi":"10.3389/fnume.2024.1481343","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gallium-68 positron emission tomography (<sup>68</sup>Ga-PET) with the two registered somatostatin analogs, [<sup>68</sup>Ga]Ga-DOTA-Tyr<sup>3</sup>-octreotide ([<sup>68</sup>Ga]Ga-DOTA-TOC) and [<sup>68</sup>Ga]Ga-DOTA-Tyr<sup>3</sup>-octreotate ([<sup>68</sup>Ga]Ga-DOTA-TATE), where DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, is routinely used for imaging of somatostatin receptor (SST)-expressing tumors. We investigated copper-61 (<sup>61</sup>Cu) as an alternative radiometal for PET imaging of SST-expressing tumors. Compared to gallium-68, copper-61 (t<sub>1/2</sub> = 3.33 h, E <i><sub>β</sub></i> <sup>+</sup> <sub>max</sub> = 1.22 MeV) can be produced on a large scale, enables late time point imaging, and has the therapeutic twin copper-67. Herein, DOTA-TOC and 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA)-TOC were labeled with copper-61 and compared with the clinically used [<sup>68</sup>Ga]Ga-DOTA-TOC.</p><p><strong>Methods: </strong>[<sup>61</sup>Cu]CuCl<sub>2</sub> was produced from an irradiated natural nickel target. DOTA-TOC and NODAGA-TOC were labeled with [<sup>61</sup>Cu]CuCl<sub>2</sub> in ammonium acetate buffer so to achieve a reaction pH of 5-6 and a temperature of 95°C for DOTA-TOC or room temperature for NODAGA-TOC. The radioligands were evaluated head-to-head <i>in vitro</i> using human embryonic kidney (HEK)-SST<sub>2</sub> cells (affinity, binding sites, cellular uptake, and efflux) and <i>in vivo</i> using HEK-SST<sub>2</sub> xenografts [PET/computed tomography (CT) imaging, biodistribution, and pharmacokinetics] and compared with [<sup>68</sup>Ga]Ga-DOTA-TOC, which was prepared using a standard procedure. Dosimetry estimates were made for [<sup>61</sup>Cu]Cu-NODAGA-TOC.</p><p><strong>Results: </strong>[<sup>61</sup>Cu]Cu-DOTA-TOC and [<sup>61</sup>Cu]Cu-NODAGA-TOC were prepared at an apparent molar activity of 25 MBq/nmol with radiochemical purities of ≥96% and ≥98%, respectively. <i>In vitro</i>, both presented a sub-nanomolar affinity for SST<sub>2</sub> (IC<sub>50</sub> = 0.23 and 0.34 nM, respectively). They were almost entirely internalized upon binding to SST<sub>2</sub>-expressing cells and had similar efflux rates at 37°C. <i>In vivo</i>, [<sup>61</sup>Cu]Cu-DOTA-TOC and [<sup>61</sup>Cu]Cu-NODAGA-TOC showed the same accumulation in SST<sub>2</sub>-expressing tumors. However, PET/CT images and biodistribution analyses clearly showed an unfavorable biodistribution for [<sup>61</sup>Cu]Cu-DOTA-TOC, characterized by accumulation in the liver and the abdomen. [<sup>61</sup>Cu]Cu-NODAGA-TOC displayed favorable biodistribution, comparable with [<sup>68</sup>Ga]Ga-DOTA-TOC at 1 h post-injection (p.i.). Notwithstanding, [<sup>61</sup>Cu]Cu-NODAGA-TOC showed advantages at 4 h p.i., due to the tumor retention and improved tumor-to-non-tumor ratios. The effective dose (2.41 × 10<sup>-3</sup> mSv/MBq) of [<sup>61</sup>Cu]Cu-NODAGA-TOC, but also the dose to the other organs and the kidneys (9.65 × 10<sup>-2</sup> mGy/MBq), suggested a favorable safety profile.</p><p><strong>Conclusion: </strong>Somatostatin receptor <sup>61</sup>Cu-PET imaging not only matches the performance of <sup>68</sup>Ga-PET at 1 h p.i. but has advantages in late-time imaging at 4 h p.i., as it provides improved tumor-to-non-tumor ratios. [<sup>61</sup>Cu]Cu-NODAGA-TOC is superior to [<sup>61</sup>Cu]Cu-DOTA-TOC <i>in vivo</i>. The use of the chelator NODAGA allows quantitative labeling with copper-61 at room temperature and enables the straightforward use of a kit formulation for simple manufacturing in medical centers.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11503464/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in nuclear medicine (Lausanne, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fnume.2024.1481343","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Gallium-68 positron emission tomography (68Ga-PET) with the two registered somatostatin analogs, [68Ga]Ga-DOTA-Tyr3-octreotide ([68Ga]Ga-DOTA-TOC) and [68Ga]Ga-DOTA-Tyr3-octreotate ([68Ga]Ga-DOTA-TATE), where DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, is routinely used for imaging of somatostatin receptor (SST)-expressing tumors. We investigated copper-61 (61Cu) as an alternative radiometal for PET imaging of SST-expressing tumors. Compared to gallium-68, copper-61 (t1/2 = 3.33 h, E β+max = 1.22 MeV) can be produced on a large scale, enables late time point imaging, and has the therapeutic twin copper-67. Herein, DOTA-TOC and 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA)-TOC were labeled with copper-61 and compared with the clinically used [68Ga]Ga-DOTA-TOC.
Methods: [61Cu]CuCl2 was produced from an irradiated natural nickel target. DOTA-TOC and NODAGA-TOC were labeled with [61Cu]CuCl2 in ammonium acetate buffer so to achieve a reaction pH of 5-6 and a temperature of 95°C for DOTA-TOC or room temperature for NODAGA-TOC. The radioligands were evaluated head-to-head in vitro using human embryonic kidney (HEK)-SST2 cells (affinity, binding sites, cellular uptake, and efflux) and in vivo using HEK-SST2 xenografts [PET/computed tomography (CT) imaging, biodistribution, and pharmacokinetics] and compared with [68Ga]Ga-DOTA-TOC, which was prepared using a standard procedure. Dosimetry estimates were made for [61Cu]Cu-NODAGA-TOC.
Results: [61Cu]Cu-DOTA-TOC and [61Cu]Cu-NODAGA-TOC were prepared at an apparent molar activity of 25 MBq/nmol with radiochemical purities of ≥96% and ≥98%, respectively. In vitro, both presented a sub-nanomolar affinity for SST2 (IC50 = 0.23 and 0.34 nM, respectively). They were almost entirely internalized upon binding to SST2-expressing cells and had similar efflux rates at 37°C. In vivo, [61Cu]Cu-DOTA-TOC and [61Cu]Cu-NODAGA-TOC showed the same accumulation in SST2-expressing tumors. However, PET/CT images and biodistribution analyses clearly showed an unfavorable biodistribution for [61Cu]Cu-DOTA-TOC, characterized by accumulation in the liver and the abdomen. [61Cu]Cu-NODAGA-TOC displayed favorable biodistribution, comparable with [68Ga]Ga-DOTA-TOC at 1 h post-injection (p.i.). Notwithstanding, [61Cu]Cu-NODAGA-TOC showed advantages at 4 h p.i., due to the tumor retention and improved tumor-to-non-tumor ratios. The effective dose (2.41 × 10-3 mSv/MBq) of [61Cu]Cu-NODAGA-TOC, but also the dose to the other organs and the kidneys (9.65 × 10-2 mGy/MBq), suggested a favorable safety profile.
Conclusion: Somatostatin receptor 61Cu-PET imaging not only matches the performance of 68Ga-PET at 1 h p.i. but has advantages in late-time imaging at 4 h p.i., as it provides improved tumor-to-non-tumor ratios. [61Cu]Cu-NODAGA-TOC is superior to [61Cu]Cu-DOTA-TOC in vivo. The use of the chelator NODAGA allows quantitative labeling with copper-61 at room temperature and enables the straightforward use of a kit formulation for simple manufacturing in medical centers.